373,346 Guardant Health, Inc. $GH Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lessened its stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 28.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 937,974 shares of the company’s stock after selling 373,346 shares during the quarter. William Blair Investment Management LLC owned approximately 0.70% of Guardant Health worth $167,297,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ninepoint Partners LP bought a new stake in shares of Guardant Health in the 2nd quarter valued at about $2,853,000. Orbimed Advisors LLC bought a new position in Guardant Health during the first quarter worth about $40,199,000. GSA Capital Partners LLP bought a new position in Guardant Health during the second quarter worth about $1,772,000. Eagle Health Investments LP bought a new position in Guardant Health during the second quarter worth about $45,112,000. Finally, SWS Partners acquired a new position in Guardant Health during the second quarter worth approximately $11,190,000. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $210.00 price objective on shares of Guardant Health in a research report on Thursday, September 10th. Stifel Nicolaus boosted their target price on Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada increased their price target on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Mizuho raised their price target on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Stephens raised their price target on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $190.88.

Get Our Latest Report on Guardant Health

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Steve E. Krognes sold 6,674 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total value of $1,172,888.76. Following the completion of the sale, the director owned 7,906 shares of the company’s stock, valued at $1,389,400.44. The trade was a 45.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Amirali Talasaz sold 37,500 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the transaction, the chief executive officer owned 37,500 shares in the company, valued at approximately $6,343,500. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,039 shares of company stock valued at $9,088,877 in the last three months. 5.60% of the stock is owned by insiders.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $151.70 on Monday. The firm has a market cap of $20.52 billion, a price-to-earnings ratio of -41.22 and a beta of 1.67. The stock’s fifty day moving average price is $168.64 and its two-hundred day moving average price is $132.99. Guardant Health, Inc. has a one year low of $74.55 and a one year high of $191.05.

Guardant Health (NASDAQ:GH – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.74) EPS. On average, equities analysts anticipate that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Guardant Health Profile

(Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.